Table 2.
Recommended Treatment in Patients Without Cirrhosis | ||||
---|---|---|---|---|
LDV/SOF | OBV/PTV/r + DSV* | SOF + SMV ± RBV | ||
Treatment duration | 12 weeks | 12 weeks | 12 weeks | |
Recommendation level | Class I, level A | Class I, level A | Class IIa, level B |
Recommended Treatment in Patients With Compensated Cirrhosis | ||||
---|---|---|---|---|
LDV/SOF | OBV/PTV/r + DSV + RBV | LDV/SOF + RBV | SOF + SMV ± RBV | |
Treatment duration | 24 weeks | 24 weeks | 12 weeks | 24 weeks |
Recommendation level | Class I, level A | Class I, level A | Class I, level B | Class IIa, level B |
DSV = dasabuvir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PEG = pegylated interferon; PTV = paritaprevir; r = ritonavir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir
The addition of ribavirin is recommended in patients with genotype 1a HCV infection.